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Abstract
Background: Oral tongue squamous cell carcinoma (OTSCC) is one of the most aggressive forms of head and
neck/oral cancer (HNOC), and is a complex disease with extensive genetic and epigenetic defects, including
microRNA deregulation. Identifying the deregulation of microRNA-mRNA regulatory modules (MRMs) is crucial for
understanding the role of microRNA in OTSCC.
Methods: A comprehensive bioinformatics analysis was performed to identify MRMs in HNOC by examining the
correlation among differentially expressed microRNA and mRNA profiling datasets and integrating with 12 different
sequence-based microRNA target prediction algorithms. Confirmation experiments were performed to further assess
the correlation among MRMs using OTSCC patient samples and HNOC cell lines. Functional analyses were performed
to validate one of the identified MRMs: miR-21-15-Hydroxyprostaglandin Dehydrogenase (HPGD) regulatory module.
Results: Our bioinformatics analysis revealed 53 MRMs that are deregulated in HNOC. Four high confidence
MRMs were further defined by confirmation experiments using OTSCC patient samples and HNOC cell lines,
including miR-21-HPGD regulatory module. HPGD is a known anti-tumorigenic effecter, and it regulates the
tumorigenic actions of Prostaglandin E2 (PGE2) by converts PGE2 to its biologically inactive metabolite. Ectopic
transfection of miR-21 reduced the expression of HPGD in OTSCC cell lines, and the direct targeting of the miR-21 to
the HPGD mRNA was confirmed using a luciferase reporter gene assay. The PGE2-mediated upregulation of miR-21
was also confirmed which suggested the existence of a positive feed-forward loop that involves miR-21, HPGD and
PGE2 in OTSCC cells that contribute to tumorigenesis.
Conclusions: We identified a number of high-confidence MRMs in OTSCC, including miR-21-HPGD regulatory module,
which may play an important role in the miR-21-HPGD-PGE2 feed-forward loop that contributes to tumorigenesis.
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Background
Head and neck/oral cancer (HNOC) is a commonly en-
countered malignancy. Head and neck squamous cell car-
cinoma (HNSCC), which arises from the epithelium lining
of this region, makes up the majority (over 90 %) of
HNOC. Oral tongue squamous cell carcinoma (OTSCC)
is one of the most aggressive form of HNSCCs, which
exhibits a propensity for rapid local invasion and spread
[1], has a distinct nodal metastasis pattern [2, 3].
OTSCC patients also suffer from a high recurrence rate
[4]. OTSCC is a complex disease with extensive genetic
and epigenetic defects, including microRNA deregula-
tion. MicroRNAs are pivotal regulators of physiological
and disease processes through their control of diverse
cellular processes. Several microRNAs have been func-
tionally classified as oncogenes or tumor suppressors, and
the aberrant expression of microRNA has been observed
in almost all cancer types including OTSCC [5–8].
Deregulation of these cancer-associated microRNAs can
significantly impact tumor initiation and progression by
activating pathways promoting uncontrolled proliferation,
favoring survival, inhibiting differentiation, and promoting
invasion [9, 10]. MicroRNAs are not directly involved
in protein coding, but are able to control the expression
of their target genes at post-transcriptional levels by
facilitating mRNA degradation and/or repressing trans-
lation. As such, the identification and detection of func-
tional microRNA-mRNA regulatory modules (MRMs)
are crucial components for understanding of micro-
RNA functions.
MicroRNAs are a class of small non-coding RNAs of
approximately 22 nucleotides in length that are en-
dogenously expressed in mammalian cells. They are re-
lated to, but distinct from, siRNAs. A key difference
between siRNA and microRNA is that siRNA requires
almost complete complementary to its targeting se-
quence for it to exert the silencing function, whereas
microRNA usually binds to its target genes through partial
complementary. While numerous sequence-based bio-
informatics methods for microRNA target prediction have
been developed, these methods often lead to high false
discovery rates [11]. In order to minimize false positives
and to detect the functional microRNA targets under a
specific biological condition, recent approaches often
integrate the microRNA and mRNA profiling analysis
in conjunction with the sequence-based target predic-
tion. Two types of experiments are common: 1) differ-
ential mRNA profiling experiment on a microRNA
transfected cell line and its negative control, and 2)
simultaneous microRNA and mRNA profiling analysis
on samples of different phenotypes (e.g., normal vs.
tumor). The first approach has been used by many
groups, including us, to define the functional micro-
RNA targets when a specific microRNA is over- or
under- expressed [12–14]. The second approach aims
to discover microRNA with altered expression related
to different phenotypes and to uncover their targets
mRNAs. This approach is based on the simple principle
that inverse relationships in their expression profiles
should be held between a specific microRNA and its
functional target genes. When integrated with the
sequence-based bioinformatics target prediction, this
approach is believed to lead to the identification of high
confidence microRNA targets.
Our group and several others have recently under-
taken extensive RNA-based surveys to identify gene ex-
pression and microRNA abnormalities in OTSCC. In
this study, we utilized our existing transcription profil-
ing dataset [15], and a meta-analysis of 13 published
microRNA profiling studies [16], and integrate them
with a collection of 12 sequence-based bioinformatics
tools to define the deregulation of functional MRMs in
OTSCC. We then evaluated these MRMs in 2 OTSCC
patient cohorts and a panel of HNSCC cell lines. With
our comprehensive approach, we identified a panel of
high confidence microRNA-mRNA regulatory modules
in OTSCC, including miR-21-15-Hydroxyprostaglandin
Dehydrogenase (HPGD) regulatory module. We also
confirmed the positive feed-forward loop that involves
miR-21, HPGD and Prostaglandin E2 (PGE2) in HNOC
cells that contribute to tumorigenesis.
Methods
MicroRNA target prediction
The microRNA target prediction was performed using the
comparative analysis function of the miRWalk [17], which
contains a collection of 10 bioinformatics tools, including
DIANAmT, miRanda, miRDB, miRWalk, RNAhybrid,
PicTar (4-way), PicTar (5-way), PITA, RNA22, TargetS-
can5.1. In addition, MicroCosm 5.0 and TargetScanHuman
6.2 were also used for predicting the microRNA targets.
For our study, genes that were predicted by at least one
method were defined as candidate microRNA targets. The
base-pairing and the minimum free energy (mfe) for the
binding of microRNA to its targeting sequences were pre-
dicted using the RNAhybrid program [18].
Cell Culture, transfection and function assays
The human HNSCC cell lines (1386Ln [19], 1386Tu
[19], 686Ln [20], 686Tu [20], CAL27 [21], SCC2 [22],
SCC4 [22], SCC9 [23], SCC15 [23], SCC25 [23], Tca8113
[24], UM1 [25], UM2 [25]) were maintained in DMEM/
F12 medium (Gibco) supplemented with 10% FBS, 100
units/ml penicillin, and 100 μg/ml streptomycin (Invi-
trogen). All cells were maintained in a humidified
incubator containing 5 % CO2 at 37 °C. For functional
analysis, hsa-miR-21 and non-targeting microRNA
mimic (Dharmacon), and gene specific siRNAs for
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COX2 and HPGD (Santa Cruz Biotechnology) were
transfected into the cells using DharmaFECT Trans-
fection Reagent 1 as described previously [26, 27]. For
PGE2 treatment, 20 μM of PGE2 or vehicle (DMSO)
was added to the cells and incubated for 24 h. For Cel-
ecoxiB treatment, 10 μM of CelecoxiB or vehicle
(DMSO) was added to the cells and incubated for 24
h. Cell proliferation was measured by MTT assay as
described previously [28].
Clinical samples from OTSCC patients
We downloaded the RNASeq and miRNASeq profiling
datasets on 12 OTSCC and paired normal tissue samples
from The Cancer Genome Atlas (TCGA) Data Protal
[tcga-data.nci.nih.gov]. The gene expression values were
extracted as normalized count, and the microRNA levels
were extracted as reads per million miRNA mapped
from the datasets. The demographics of the patients
were as follows: 6 male, 6 female and average age = 62
(range: 36–88), 1 stage T1 cases, 5 stage T2 cases, 3
stage T3 case and 3 T4 cases. Oral cytology samples
were obtained from 13 patients with pathologically
characterized primary OSCC of the tongue before
tumor resection (including 6 stage T1 cases 6 stage T2
cases and 1 stage T3 case) as previously described [29,
30]. These procedures are in compliance with the
Helsinki Declaration, and was approved by the Ethical
Committee of the First Affiliated Hospital, Sun Yat-Sen
University (reference number: 2014-C-001). The informed
consent was obtained from participants. Patients were
excluded if there is a history of lung carcinoma or HNSCC
elsewhere and may represent metastatic disease. The
demographics of the patients were as follows: 8 male, 5
female and average age = 51.8 (range: 32–78). The total
RNA was isolated using miRNeasy Mini kit (Qiagen), and
quantified by a spectrophotometer or the RiboGreen RNA
Quantitation Reagent (Molecular Probes).
Quantitative RT-PCR Analysis
The relative microRNA levels were determined by Taq-
Man microRNA assays (Applied Biosystems) as previ-
ously described [16, 31]. The relative mRNA levels were
determined by quantitative two-step RT-PCR assay with
pre-designed gene specific primer sets (Origene) as de-
scribed before [16, 31]. The relative microRNA and
mRNA levels were computed using the 2-delta delta Ct
analysis method, where U6 and beta-actin were used as
internal controls, respectively.
Western-blot analysis
Western blots were performed as described previously
[16] using antibodies specific for HPGD (Cayman Chem-
ical) and beta-actin (Sigma-Aldrich) and an immuno-star
HRP substrate Kit (Bio-RAD).
Fluorescent immunocytochemical analysis
Immunofluorescence analysis was performed as previ-
ously described [16]. In brief, cells were cultured on 8
chamber polypropylene vessel tissue culture treated glass
slides (Millipore) fixed with cold methanol, perme-
abilized with 0.5 % Triton X-100/PBS, and blocked with
1% BSA in PBS. The slides were incubated with primary
antibodies against HPGD (1:500, Cayman Chemical).
The slides were then incubated with a FITC-conjugated
anti-rabbit IgG antibody (1:50, Santa Cruz). The slides
were mounted with ProLong Gold antifade reagent con-
taining DAPI (Invitrogen) following the manufacturer’s
protocol. The slides were then examined with a fluores-
cence microscope (Carl Zeiss).
Dual-Luciferase reporter assay
The luciferase reporter gene constructs (pGL-E1 and
pGL-E2E3) were created by cloning a 55-bp fragment
from the 3′-UTR (position 2625–2680 of the HPGD
mRNA sequence NM_000860, containing the miR-21 site
E1) and a 61-bp fragment from the 3′-UTR (position
2860–2921 of the HPGD mRNA sequence NM_000860,
containing the miR-21 targeting sites E2 and E3) into the
Xba I site of the pGL3-Control firefly luciferase reporter
vector (Promega) as described previously [9]. The corre-
sponding mutant constructs (pGL-E1m, pGL-E2mE3,
pGL-E2E3m and pGL-E2mE3m) were created by re-
placing the seed regions (positions 2–8) of the miR-21
binding sites with 5′-TTTTTTT-3′. All constructs were
verified by sequencing. The reporter constructs and the
pRL-TK vector (Promega) were co-transfected using Lipo-
fectamine 2000 (Invitrogen). The luciferase activities were
then determined as described previously [26] using a Glo-
Max 20/20 luminometer (Promega). Experiments were
performed in quadruplicate.
Statistical analysis
Data was analyzed using the Statistical Package for
Social Science (SPSS), version 17.0. Student’s t-test was
used to compare differences between groups. Pearson’s
correlation coefficient was computed for examining the
relationship between the expression of microRNA and
their target genes. For all analyses, p < 0.05 was consid-
ered statistically significant.
Results
We first developed a list of putative microRNA-mRNA
regulatory modules (MRMs) based on the simple
principle that inverse relationships should be anticipated
in the expression of a specific microRNA and its func-
tional target gene (mRNA). We used a total of 97 differ-
entially expressed coding genes (44 up-regulated and 53
down-regulated mRNAs, see Additional file 1: Table S1A
and S1B, respectively) and 9 differentially expressed
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Table 1 Putative microRNA-mRNA regulatory module defined by microRNA up-regulation and mRNA down-regulationa
Putative miR-mRNA regulatory module Bioinformatics
Predictionc
Correlation (TCGA dataset)d Correlation (HNSCC cell line)e Correlation (patient sample)f
miR (up)b mRNA (down)b Pearson r p value Pearson r p value Pearson r p value
hsa-miR-155 ADH1B 6 −0.3263 0.120034 −0.0317 0.914331
hsa-miR-31 ADH1B 3 −0.3651 0.079472 0.3863
hsa-miR-223 ADIPOQ 5 −0.3104 0.140425 0.476
hsa-miR-130b ADIPOQ 3 −0.3612 0.083075 0.2356
hsa-miR-223 ALOX12 5 −0.2752 0.193414 0.5856
hsa-miR-130b ATP1A2 6 −0.4324 0.035023 −0.1899 0.515529
hsa-miR-31 ATP1A2 3 −0.3265 0.120034 0.2494
hsa-miR-223 CEACAM5 6 −0.0421 0.845504 −0.1689 0.563792
hsa-miR-21 CEACAM5 5 −0.107 0.618738 −0.0834 0.776829
hsa-miR-130b CEACAM5 4 −0.1968 0.358677 −0.2497 0.389269
hsa-miR-223 CEACAM7 6 −0.111 0.605605 −0.1364 0.641958
hsa-miR-21 CILP 5 −0.4095 0.047201 −0.1815 0.534608
hsa-miR-21 CLU 3 −0.4126 0.045447 −0.1612 0.581947
hsa-miR-31 EMP1 5 −0.1491 0.487134 −0.0997 0.7345
hsa-miR-130b EMP1 4 −0.5049 0.012034 0.0951
hsa-miR-21 GPD1L 5 −0.6784 0.000269 −0.4509 0.105628 −0.9536 0.00001
hsa-miR-155 GPD1L 5 −0.3008 0.154363 0.208
hsa-miR-223 HLF 7 −0.5536 0.005067 0.0789
hsa-miR-31 HLF 6 −0.5107 0.010896 0.2482
hsa-miR-130b HLF 6 −0.62 0.001231 0.067
hsa-miR-21 HLF 3 −0.7801 <0.00001 −0.5774 0.0307 −0.6707 0.048
hsa-miR-31 HPGD 6 −0.2577 0.225391 0.0659
hsa-miR-21 HPGD 6 −0.55 0.005363 −0.5841 0.0283 −0.7972 0.0011
hsa-miR-130b HPGD 3 −0.4602 0.023715 −0.3617 0.203821
hsa-miR-21 ID4 5 −0.5229 0.008886 −0.1121 0.702802
hsa-miR-31 KRT15 3 −0.1438 0.505031 −0.0053 0.985653
hsa-miR-21 LEPR 5 −0.2902 0.169251 0.6053
hsa-miR-223 LEPR 4 −0.1443 0.502026 −0.3246 0.257504
hsa-miR-130b MGLL 4 −0.6913 0.000183 −0.5158 0.05903 −0.1864 0.542035
hsa-miR-223 NEBL 6 −0.518 0.009519 −0.0598 0.8391
hsa-miR-130b NEBL 5 −0.5237 0.008733 0.091
hsa-miR-21 NEBL 3 −0.5582 0.004605 −0.1793 0.539655
hsa-miR-223 NMU 5 −0.2119 0.322319 0.6125
hsa-miR-31 PPP1R3C 4 −0.2695 0.203707 0.5588
hsa-miR-155 PTN 6 0.1331 −0.1157 0.693673
hsa-miR-130b TGM1 7 −0.5858 0.002676 0.0162
hsa-miR-155 ZNF185 6 −0.0065 0.977802 −0.2152 0.46
hsa-miR-21 ZNF185 5 −0.3451 0.098725 −0.0739 0.8018
aThe putative microRNA-mRNA regulatory module (MRM) was constructed based on microRNA and mRNA expression profiles of OTSCC, as we previously reported
in [16] and [15], respectively
bDifferential expression of microRNAs and mRNAs was validated using dataset on 12 OTSCC and paired normal tissue samples that were extracted from TCGA.
Genes that show statistically significant differential expression were identified with bold font
cThe candidate targets of a microRNA were predicted using a collection of 12 bioinformatics tools, including DIANAmT, miRanda, microCosm, miRDB, miRWalk,
RNAhybrid, PicTar (4-way), PicTar (5-way), PITA, RNA22, TargetScan5, and TargetScanHuman 6.2. The number of bioinformatics tools (out of a total of 12 tools
tested here) that predict a gene to be a microRNA target was presented. The gene/microRNA pairs predicted by at least 3 tools were listed in the table
dCorrelations of microRNA and mRNA levels were assessed using dataset on 12 OTSCC and paired normal controls that were extracted from TCGA. Inverted
correlation (negative Pearson r value) is expected for a MRM, and p value was calculated
eCorrelations of microRNA and mRNA levels were assessed by quantitative real-time PCR based on 13 HNSCC cell line. Inverted correlation (negative Pearson
r value) is expected for a MRM, and p value was calculated
fCorrelations of 4 pairs of microRNA and mRNA levels were assessed by quantitative real-time PCR based on 13 OTSCC patient oral cytology samples. Inverted
correlation (negative Pearson r value) is expected for a MRM, and p value was calculated
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microRNAs (5 up-regulated and 4 down-regulated
microRNAs, see Additional file 1: Table S1C) from our
previous genomic profiling studies on OTSCC [15, 16]
for the development of this putative MRMs list. This
putative MRMs list consists of 265 putative MRMs
defined by microRNA up-regulation and mRNA down-
regulation, and 176 putative MRMs defined by micro-
RNA down-regulation and mRNA up-regulation. We
then tested these putative MRMs using a panel of 12
different sequence-based microRNA target prediction
algorithms (DIANAmT, miRanda, microCosm, miRDB,
miRWalk, RNAhybrid, PicTar (4-way), PicTar (5-way),
PITA, RNA22, TargetScan5.1, and TargetScanHuman6.2)
to refine our putative MRMs list. A total of 132 candidate
MRMs were identified (predicted as microRNA target by
at least 1 bioinformatics algorithm, see Additional file 2:
Table S2A and Additional file 3: Table S2B). As shown in
Table 1, 38 potential MRMs were predicted by at least 3
bioinformatics target prediction algorithms, where the
up-regulation of the microRNA contributes to the
down-regulation of mRNA, and 15 potential MRMs
were predicted by at least 3 bioinformatics target pre-
diction algorithms (Table 2), where down-regulation of
the microRNA contributes to the up-regulation of mRNA.
The differential expression of microRNAs and coding
genes (mRNAs) involved in these 53 potential MRMs (9
microRNAs and 34 mRNAs) was then validated using
dataset on 12 OTSCC and paired normal tissues (ex-
tracted from TCGA Data Portal). As shown in Additional
file 4: Table S3, statistically significant differential expres-
sion was observed for 8 out of 9 microRNAs and 23 out
of 34 mRNAs tested in the validation OTSCC cohort.
To further evaluate these potential MRMs, we exam-
ined the correlative relationship between the microRNA
levels and the expression of their target genes in these
12 OTSCC and 12 paired normal tissues (extracted from
TCGA Data Portal), as well as 13 HNSCC cell lines
(Table 1 and Fig. 1). Among these 53 microRNA-
mRNA pairs tested, 4 exhibited apparent inverse corre-
lations in both OTSCC tissue samples and HNSCC cell
lines (miR-21-GPD1L, miR-21-HLF, miR-21-HPGD and
miR-130b-MGLL, with Pearson’s correlation coefficient
r = −0.6784, −0.7801, −0.55, −0.6913 for OTSCC tissue
samples, and r = −0.4509, −0.5774, −0.5841, and −0.5158
for HNSCC cell lines, respectively). The inverse correla-
tions for miR-21-GPD1L, miR-21-HLF, miR-21-HPGD
and miR-130b-MGLL were statistically significant in
OTSCC tissue samples, and the inverse correlations for
Table 2 Putative microRNA-mRNA regulatory module defined by microRNA down-regulation and mRNA up-regulationa
Putative miR-mRNA regulatory module Bioinformatics
Predictionc
Correlation (TCGA dataset)d Correlation (HNSCC cell line)e
miR (down)b mRNA (up)b Pearson r p value Pearson r p value
hsa-miR-375 COL4A6 5 −0.3145 0.13511 0.2432
hsa-miR-375 COL5A1 5 −0.3659 0.079472 −0.2159 0.4585
hsa-miR-125b COL5A1 5 −0.437 0.03274 −0.0325 0.9122
hsa-miR-375 COL5A2 5 −0.3708 0.075136 −0.231 0.426861
hsa-miR-375 CXCL1 4 −0.0864 0.689479 0.7146
hsa-miR-125b CXCL13 6 −0.3346 0.110688 −0.1736 0.552828
hsa-miR-375 DFNA5 4 −0.4936 0.014374 −0.0855 0.771344
hsa-miR-100 FSTL4 3 −0.0923 0.668975 −0.1796 0.538966
hsa-miR-99a FSTL4 3 −0.1413 0.511067 −0.1847 0.527303
hsa-miR-125b HMGA2 5 −0.4628 0.023036 −0.0557 0.849995
hsa-miR-375 IFI44L 4 −0.1937 0.366226 0.42
hsa-miR-125b IGFBP3 4 −0.3656 0.079472 −0.2774 0.336959
hsa-miR-125b LAMC2 5 −0.6952 0.000164 0.3459
hsa-miR-375 LAMC2 3 −0.4309 0.035971 0.4508
hsa-miR-375 ODC1 3 −0.2375 0.264826 −0.1239 0.673024
aThe putative microRNA-mRNA regulatory module (MRM) was constructed based on microRNA and mRNA expression profiles of OTSCC, as we previously reported
in [16] and [15], respectively
bDifferential expression of microRNAs and mRNAs was validated using dataset on 12 OTSCC and paired normal tissue samples that was extracted from TCGA.
Genes that show statistically significant differential expression were identified with bold font
cThe candidate targets of a microRNA were predicted using a collection of 12 bioinformatics tools, including DIANAmT, miRanda, microCosm, miRDB, miRWalk,
RNAhybrid, PicTar (4-way), PicTar (5-way), PITA, RNA22, TargetScan5, and TargetScanHuman 6.2. The number of bioinformatics tools (out of a total of 12 tools
tested here) that predict a gene to be a microRNA target was presented. The gene/microRNA pairs predicted by at least 3 tools were listed in the table
dCorrelations of microRNA and mRNA levels were assessed using dataset on 12 paired OTSCC and normal controls that was extracted from TCGA Data Portal.
Inverted correlation (negative Pearson r value) is expected for a MRM, and p value was calculated
eCorrelations of microRNA and mRNA levels were assessed by quantitative real-time PCR based on 13 HNSCC cell line. Inverted correlation (negative Pearson
r value) is expected for a MRM, and p value was calculated
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miR-21-HLF and miR-21-HPGD were also statistically sig-
nificant in HNSCC cell lines.
We further evaluated these 4 MRMs in oral cytology
samples from 13 OTSCC cases, and statistically signifi-
cant inverse correlations were observed for miR-21-
GPD1L, miR-21-HLF, and miR-21-HPGD, but not for
miR-130b-MGLL (r = −0.9536, p = 0.00001; r = −0.6707,
p = 0.048; r = −0.7972, p = 0.0011; and r = −0.1864, p =
0.542035; Table 1 and Fig. 1).
We further explore the interaction of miR-21 and
HPGD in our study. As shown in Fig. 2a, ectopic trans-
fection of miR-21 mimic to UM1, UM2, SCC9 and
Tca8113 cells led to a statistically significant reduction
in HPGD mRNA level as compared to cells treated with
control mimic. The miR-21 has no apparent effect on
HPGD expression in HeLa cells. As shown in Fig. 2b
and c, ectopic transfection of miR-21 mimic to UM1
cells led to reduced HPGD expression at protein level
and reduced immunostaining of HPGD, respectively, as
compared to the cells treated with control mimic. As
shown in Fig. 2d, ectopic transfection of miR-21 mimic
also enhanced the proliferation of OTSCC cells, which is
consistent with previous observations [10, 32], and con-
firmed the oncogenic effect of miR-21.
Bioinformatics analysis revealed that there are three
miR-21 targeting sites located in the 3′-UTR of the
HPGD mRNA (E1 at position 2652 to 2671, E2 at pos-
ition 2880 to 2901, E3 at 2890 to 2911) and the targeting
sites E2 and E3 are partially overlapped (Fig. 3a). The
predicted minimum free energy (mfe) for the binding of
these sites to miR-21 are −17.6, −11.4 and −16.5 kcal/
mol, respectively. To test whether the miR-21 directly
interacts with these predicted targeting sites in HPGD
mRNA, dual luciferase reporter assays were performed
using constructs containing these targeting sites (Fig. 3b).
When cells were transfected with miR-21, the luciferase
activities of the construct containing targeting site E1
(pGL-E1) was significantly reduced as compared to the
cells transfected with negative control. When the seed
region of this targeting site was mutated (pGL-E1m), the
effect of miR-21 on the luciferase activity was abolished.
For sites E2 and E3, when cells were transfected with
miR-21, the luciferase activities of the construct contain-
ing both targeting sites E2 and E3 (pGL-E2E3) was not
changes as compared to the cells transfected with negative
control. Interestingly, when the seed region of E2 was mu-
tated (pGL-E2mE3), the miR-21-mediated down-regulation
















































































































































































































Fig. 1 Correlation of microRNAs and the expression of their target genes in OTSCC. The levels of miR-21 and miR-130b and the expression of
HPGD, GPD1L, HLF and MGLL were extracted for 12 OTSCC and paired normal tissue samples from The Cancer Genome Atlas (TCGA) (a, d, g, j),
assessed by qRT-PCR on 13 HNSCC cell lines (b, e, h, k), and on 13 oral cytology samples from OTSCC patients (c, f, i, l). The correlation of the
miR-21 level with the expression of GPD1L (a, b, c), HLF (d, e, f), HPGD (g, h, i), and the correlation of miR-130b level with the expression of MGLL
(j, k, l) were assessed, and the Pearson’s correlation coefficient (r) was calculated
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on constructs with E3 mutation (pGL-E2E3m) or muta-
tions of both E2 and E3 (pGL-E2mE3m).
As shown in Fig. 4a and b, both siRNA-mediated
knockdown of COX2 and treatment with COX2 inhibi-
tor (CelecoxiB) led to down-regulation of miR-21 in
UM1 cells. As shown in Fig. 4c, directly apply PGE2 to
the UM1 cells led to the up-regulation of miR-21, and
knockdown of HPGD (Fig. 4d) also led to the up-
regulation of miR-21. As anticipated, treating cells with
PGE2 and CelecoxiB led to up-regulation and down-
regulation of cell proliferation, respectively, which is
consistent with previous observations [33, 34] (Fig. 4e).
These results are in agreement with observation made by
Lu et al. in cholangiocarcinoma [35], which confirm the
PGE2-mediated miR-21 up-regulation in OTSCC and sug-
gest a PGE2-miR-21-HPGD positive feed-forward loop
that contributes to tumorigenesis (Fig. 4f).
Discussion
Despite the significant increase in the number of experi-
mentally validated microRNA-mRNA regulatory rela-
tionships, the majority of the microRNA targeted genes
remains unknown. MicroRNA usually binds to its target
genes through partial complementary. While numerous
sequence-based bioinformatics methods for microRNA
target prediction have been developed, these methods
often lead to high false discovery rates [11]. However,
the integration of these bioinformatics tools with
mRNA/microRNA differential expression profiles often
lead to the identification of high confidence microRNA-
mRNA regulatory modules. In this study, we carried out
this integrated analysis to identify MRMs in two steps.
First, based on the simple principle that inverse relation-
ships should be anticipated in the expression of a spe-
cific microRNA and its functional target genes, we
developed a list of putative microRNA-mRNA regula-
tory modules by linking each microRNAs with all in-
versely regulated mRNAs based on the results of our
previous mRNA and microRNA profiling studies on
OTSCC [15, 16]. The second step is to these putative
MRMs bioinformaticsly using sequence-based micro-
RNA target prediction algorithm. Since there are many
available sequence-based microRNA target prediction
tools, and each of these tools utilizes a different model
to define targeting sequences that are associated with
functionality, the predictions differ when applied to the
same microRNAs, with each method having different
levels of coverage and false positive prediction [11]. In
order to reduce the potential false positives, we used a vot-
ing scheme to combine the predictions from the 12 com-
monly used bioinformatics tools, including DIANAmT,
miRanda, microCosm, miRDB, miRWalk, RNAhybrid,
PicTar (4-way), PicTar (5-way), PITA, RNA22, TargetS-
can5.1, and TargetScanHuman6.2. With this integrated
approach, we developed a list of 53 potential MRMs that
are differentially expressed in OTSCC.
Since the microRNA regulates its target gene mainly














































































Fig. 2 MiR-21-mediated down-regulation of HPGD and up-regulation of proliferation. a miR-21 mimic and negative control mimic were introduced
into the UM1, UM2, SCC9 Tca8113 and HeLa cells. qRT-PCR was performed to assess the expression of HPGD. b Western blot was performed to assess
the expression of HPGD at protein level in UM1 cells treated with either miR-21 mimic or negative control mimic. c The expression HPGD was
measured by fluorescent immunocytochemical analysis in UM1 cells treated with either miR-21 mimic or negative control mimic (Green: HPGD; Blue:
DAPI nuclear staining). d The UM1 and Tca8113 cells were treated with miR-21 mimic or negative control mimic, and the cell proliferation was assessed
by MTT assay. Data represents at least 3 independent triplicate experiments with similar results. * indicates p < 0.05
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the levels of microRNA and mRNA pair is a key charac-
teristic of a functional MRM. We further prioritized the
list of differentially expressed MRMs in OTSCC by
examining the correlative relationship between the
microRNA levels and the expression of their target
genes in 3 sets of samples (12 OTSCC and 12 paired
normal tissues, 13 HNSCC cell lines, and 13 oral cy-
tology samples from OTSCC cases). This comprehen-
sive prioritization step led to 4 promising MRMs,
including miR-21-GPD1L, miR-21-HLF, miR-21-HPGD
and miR-130b-MGLL.
Deregulations of miR-21 and miR-130b, as well as de-
regulation of GPD1L, HLF, HPGD and MGLL have
been reported either in HNOC or other cancer types
[15, 16, 36–42], and these MRMs represent significant
functional relevance in OTSCC. GPD1L has the
glycerol-3-phosphate dehydrogenase enzyme activity
and is a regulator of HIF-1α stability [40]. And a recent
study showed that the GPD1L expression is a strong
predictor for local recurrence and survival in HNSCC
[39]. HLF belongs to the PAR (proline and acidic amino
acid-rich) subfamily of bZIP transcription factors [43,
44], and plays a role in development and circadian
rhythm regulation in the mammalian. HLF fusion pro-
teins that resulted from chromosomal translocation
(e.g., E2A-HLF) are often linked to leukemia. However,
the role of HLF in OTSCC is not entirely clear. MGLL
is involved in Prostaglandin E2 (PGE2) production in
response to inflammation and infection which leads to
fever [45]. Arachidonic acid (AA), a precursor for
PGE2, is typically liberated from AA-containing phos-
pholipids by the action of phospholipases A2 (PLA2s).
MGLL is a monoacylglycerol lipase which hydrolyzes 2-
arachidonoylglycerol (2-AG), an endocannabinoid that
functions in the central nervous system, to AA and gly-
cerol, representing an alternative AA-producing path-
way. MGLL may also play a role in certain types of
cancer by regulating both endocannabinoid and fatty























































Fig. 3 MiR-21 direct targeting HPGD mRNA. a Three predicted miR-21 targeting sites (E1, E2, E3) are located in the 3′-UTR of HPGD mRNA. The
numbers under the diagram are the starting bp-position of the seed regions for the miR-21 targeting sites. The base-pairing and the minimum
free energy (mfe) for the binding of miR-21 to the targeting sequences were predicted using the RNAhybrid program [18]. b Dual luciferase
reporter assays were performed to test the interaction of miR-21 and its targeting sequences in the HPGD mRNA using constructs containing
the predicted targeting sequences (pGL-E1 and pGL-E2E3) and mutated targeting sequences (pGL-E1m, pGL-E2mE3, pGL-E2E3m, pGL-E2mE3m)
cloned into the 3′-UTR of the reporter gene. Data represent at least 3 independent experiments with similar results. *: p < 0.05
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acid pathways, and supporting protumorigenic metabol-
ism [46]. This appears to be contradict with the apparent
down-regulation of MGLL observed in OTSCC [15], and
the miR-130b-MGLL regulatory module predicted here.
Nonetheless, whether MGLL plays a role in OTSCC and,
if so, by what mechanism are questions that remain un-
answered. HPGD is a known anti-tumorigenic effecter,
and it regulates the tumorigenic actions of Prostaglandin
E2 (PGE2) by converts PGE2 to its biologically inactive
metabolite, and down-regulation of HPGD has been ob-
served in many human cancer types [47–53]. Since miR-
21 is one of the most consistently observed up-regulated
microRNA in OTSCC [16, 54], the miR-21-HPGD regula-
tory module may represents a critical mechanism of regu-
lating PGE2 signaling.
Our functional study confirmed the effect of miR-21
on HPGD expression level, and the direct interaction of
miR-21 with the HPGD mRNA in OTSCC cells. We
identified three miR-21 targeting sites located in the 3′-
UTR of the HPGD mRNA, including a previously
reported site (E1) [35], and two partially overlapped sites
(E2 and E3). While we confirmed the miR-21-mediated
and E1 site-dependent target gene downregulation, E2
and E3 sites appear to have no effect. This may be be-
cause that targeting sites E2 and E3 are partially over-
lapped, and may interfere with the proper interaction
with the RISC complex. The elimination of E2 may par-
tially restore the capability of E3 (which has a stronger
binding affinity among the two sites) to binding to the
RISC complex. This is different than our previous obser-
vation where miR-138 was able to interact with multiple
overlapping target sites on the FOSL1 mRNA [55]. Add-
itional studies are needed to explore this mutual exclu-
sive phenomenon among multiple targeting sites. The
HPGD gene has 6 known transcript variants (NCBI ac-
cession: NM_000860, NM_001145816, NM_001256301,
NM_001256305, NM_001256306, NM_001256307), and
all 6 variants have the same 3′-UTR. As such, the inter-
action between miR-21 and HPGD mRNA is not likely
to be affected by alternative splicing. Interestingly, we
did not observe any miR-21 effect on HPGD expression
in HeLa cells (a cell line that originated from a cervical
cancer case). It is possible that this apparent difference
in the miR-21 effect on HPGD expression may be due to
differences in cancer types. It is worth noting that the ef-
fect of miR-21 on HPGD expression has also been ob-
served in other cancer type [35]. Alternatively, this
difference may be cell-line specific. HeLa cells (or the
OTSCC cell lines used here) may have specific muta-
tion(s) that dictate the miR-21 effects on HPGD. More
in-depth functional analysis will be needed to fully
evaluate the miR-21-HPGD regulatory module in differ-
ent cancer types and in other biological systems.
The levels of COX2 and its catalytic product PGE2 are
increased in a variety of malignancies, including HNOC
[56–59]. The tumorigenic actions of PGE2 are attribut-
able to its modulation of cell proliferation, survival, mi-
gration, and invasion. The level of PGE2 is controlled
by the status of PGE2 synthesis and degradation.
Whereas the cyclooxygenases (COX1 and COX2) are
rate-limiting key enzymes that control PGE2 biosyn-
thesis, HPGD is a key enzyme that converts PGE2 to its
biologically inactive metabolite, 13,14-dihydro-15-keto-
PGE2, thus leading to PGE2 inactivation [60, 61]. Con-
sistent with the antitumorigenic effect of HPGD, the
down-regulation of HPGD has been observed in many
human cancer types [47–53]. Lu et al., first reported
the PGE2-mediated up-regulation of miR-21 in cholan-
giocarcinoma, and suggested a positive feed-forward
loop that involves PGE2, miR-21 and HPGD [35]. Our
results are consistent with these previous observations,
and confirm the existence of a PGE2-miR-21-HPGD
positive feed-forward loop in OTSCC that contributes











































































































































Fig. 4 PGE2 regulates its own degradation by regulating miR-21
and its target gene HPGD. UM1 cells were treated with either
control siRNA or specific siRNAs against COX2 (a), or treated with
either COX2 inhibitor CelecoxiB or vehicle (b), or treated with either
PGE2 or vehicle (c), or treated with either control siRNA or specific
siRNAs against HPGD (d). The relative level of miR-21 was assessed
by qRT-PCR. e UM1 cells were treated with PGE2, CelecoxiB or vehicle,
and the cell proliferation was assessed by MTT assay. Data represent at
least 3 independent experiments with similar results. *: p < 0.05.
f Potential role of the positive feed-forward loop among PGE2,
miR-21 and PHGD in OTSCC
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Conclusions
In summary, we identified a number of high-confidence
MRMs in OTSCC, including miR-21-GPD1L, miR-21-
HLF, miR-21-HPGD and miR-130b-MGLL regulatory
modules. Among these MRMs, miR-21-HPGD regula-
tory module may play an important role as part of a
feed-forward loop that regulates the PGE2 signaling.
Such a feed-forward regulatory mechanism likely plays a
critical role in OTSCC initiation and progression. Thus,
combining the COX2 inhibitor-based therapies with
miR-21 inhibitors may represent a promising therapeutic
strategy for treating patients with OTSCC.
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